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Abstract
The successful use of biologicals in the treatment of rheumatoid
arthritis, psoriatic arthritis and spondyloarthritis has had a major
impact on the management of these conditions. The challenge in
the development of gene therapy as an alternative to these current
treatments is to demonstrate that such therapy is more
advantageous for patients from the therapeutic and safety points of
view. Also, it will need to be demonstrated that gene therapy for
the arthritides is economically feasible and that patient populations
worldwide will be able to access these treatments.
Introduction
Gene therapy for arthritis has been the subject of several
recent reviews [1-5], in which the targets, vectors and
methods of delivery are well documented. Interestingly, many
of the titles of these reviews contain a question mark, as does
the present commentary. This is because, in contrast to other
areas of medical research in which gene therapy is proposed,
in the arthritides biological therapy is already having great
impact and some of the side effects can be prevented. This
poses great challenges to gene therapists involved in this
area.
Current biological therapies in arthritis and
their limitations
It has been proposed that complete remission of early
rheumatoid arthritis may be possible with anti-tumour
necrosis factor (TNF) therapy [6,7]. However, uncertainties
persist regarding whether diagnosis is accurate at this early
stage of disease; furthermore, access to facilities for early
detection and availability of expensive anti-TNF treatment are
still limited by lack of government funds. Differences in
funding available for anti-TNF therapy in countries of the
western world are dramatic (IMS Market Research,
September 2004 unpublished, and G Panayi, personal
communication), and in the UK only part of the population has
access. With the increased use of anti-TNF therapy in other
clinical conditions [8], pressure to provide access will have
important economic implications. However, it is likely that,
with the availability of additional biologicals, market forces
may help to reduce prices.
Surprisingly, different anti-TNF drugs have different
therapeutic properties [8]. This is partly due to the effector
properties of their Fc portion, the different pharmacokinetics
of the agents (resulting from different routes of delivery), and
the immunogenicity of each particular compound, which in
turn depends on each patient’s immune repertoire.
State of gene therapy in arthritis
A recent search of the PubMed database revealed that during
the past 14 years we have seen an increase in the number of
papers published related to gene therapy and arthritis. This
activity peaked in 2000–2001, with 132 publications,
decreasing to 85 in the period 2003–2004. These numbers
are small when compared with the numbers of publications
on gene therapy in cancer or cardiovascular disease, which
have been relatively stable since the year 2000 at about
2100 and 500 papers per year, respectively. This difference
in publication numbers reflects both the urgent need for
alternative treatments and the different ethical issues raised in
the treatment of fatal diseases such as cancer and
cardiovascular disease in comparison with nonfatal diseases
such as arthritis.
Does this mean that research into gene therapy for arthritis is
in decline? The answer is probably ‘no’. Gene transfer is also
an important tool with which to elucidate the pathogenesis of
disease and to probe new potential molecular interventions.
The current success with biologicals, the fact that patients
will not enrol in new clinical trials unless they have failed to
respond to biological therapies, and the serious adverse
events reported in certain trials of virus-mediated gene
therapy are helping to focus the minds of gene therapists.
Despite the above factors, phase I clinical trials in arthritis
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using both in vivo and ex vivo gene therapy approaches have
been conducted [9] and some are ongoing [3].
The way forward
All of the successful biological therapies mentioned above
are expensive and must be administered to the individual for
the rest of their life. Cessation of treatment is normally
accompanied by disease relapse. Most of these biologicals
are cytokine inhibitors based on immunoglobulin backbones.
Thus, they exert their effects by inhibiting the actions of
cytokines, and their pharmacokinetics are relatively similar.
Some questions remain to be answered. For example, will
delivery of anti-inflammatory cytokines that could affect pro-
inflammatory cytokine production as well as initiate repair and
signalling cascades be more effective than cytokine
inhibitors? Could cytokine delivery be engineered to be
targeted and more effective? Can cytokine therapy accelerate
the repair process, thereby shortening the duration of
administration and thus reducing costs? These questions will
be difficult to address using protein therapy because the half-
life of cytokines is shorter than that of immunoglobulin-based
molecules, and they have pleiotropic effects due to receptor
expression in many tissues. Systemic delivery of cytokines
has several limitations, although these can be overcome by
targeting their activation to sites of disease through protein
engineering to generate latent cytokines [10,11] or by
building immunocytokines [12,13].
Gene delivery is an important tool that may help to address
the limitations of cytokine therapy mentioned above and
permit local cytokine delivery in a safe and effective manner,
as has already been demonstrated in many studies
conducted in animal models of arthritis. Local production and
local consumption of cytokines can be achieved by
engineering autologous cells that target the joints or by direct
delivery. The proposed use of stem cells for cartilage repair
will necessitate genetic engineering, at least for local immune
suppression [14,15].
Planning a safe clinical trial in arthritis
As we pointed out previously [1,4], safety is of prime concern
when treating a nonfatal chronic disease such as rheumatoid
arthritis. Any delivery system should be nonimmunogenic.
Hence, of the available viral vectors, both retrovirus and
adeno-associated virus could be considered, as well as
naked DNA. The hydrodynamic delivery of naked DNA to
muscle and liver has revealed a new important paradigm to
achieve nonviral, long-term gene expression [16,17] that
seems amenable to scaling up for human intervention.
The limited clinical experience to date with use of constitutive
promoters that express cytokine inhibitors has not yet shown
any safety issues. However, because of the relapsing and
remitting phases of disease, use of transcriptionally regulated
vectors to achieve cytokine expression will be extremely
important [18], adding another layer of safety to gene
therapy.
Local delivery could be advantageous, and the major efforts
have been in this direction. Elegant studies using retrovirally
transduced lymphocytes, as carriers of therapeutic genes,
have been conducted in animal models [19-21]. However,
this approach needs further research if we are to unravel the
changes that occur in these lymphocytes and to develop the
capacity to switch off gene expression or destroy the lympho-
cytes in case of an adverse event. The use of autologous
synoviocytes expressing interleukin-1 receptor antagonist has
been the main thrust of the phase I clinical trials to date [3,9].
Whether this approach will be therapeutic and cost-effective
is not yet clear.
Direct delivery of adeno-associated virus constitutively
expressing a TNF receptor–immunoglobulin fusion protein to
the joint is already underway, but this vector may not permit
tight transcriptional regulation because it can only package a
restricted amount of genetic information [22]. Whether this
delivery system will be safe in the long term remains to be
assessed.
It is our view that systemic hydrodynamic delivery of plasmid
DNA appears to be the most feasible and efficient procedure,
and should be further investigated. It will be important at first
to determine whether the technology is capable of delivering
similar levels of anti-TNF in the blood as are measured in the
clinical trials with infliximab or etanercept, because the
toxicology, immunogenicity and pharmacodynamics of the
anti-TNF compounds are well established. Using trans-
criptional control will be of utmost importance, as explained
above. If this approach is safe and successful in achieving
clinical benefit in the long term, a second phase of clinical
studies could be developed using combinations of anti-TNF
therapy with methotrexate, or using latent cytokines and their
combination with cartilage anabolic factors to facilitate rapid
repair of damaged joint tissue.
Conclusion
The future for gene therapy in rheumatoid arthritis seems
clearer and more defined, thanks to many new developments
in gene transfer, gene regulation and drug design.
Competing interests
The author is founder of Stealthyx Therapeutics Ltd, which
develops latent cytokines and other peptide-based
therapeutics.
Acknowledgements
The author acknowledges the financial support of the Arthritis
Research Campaign, UK, the Wellcome Trust, Kinetique Biomedical
Research Fund, the European Commission (FP5 and FP6), and contin-
uing collaboration with and support from Dr David Gould and Mrs Gill
Adams. I wish to thank Drs George Kitas and Nick Rapson for fruitful
discussions, Dr Lorna Layward for reviewing the manuscript, and
Nathan Fox for secretarial assistance.229
References
1. Chernajovsky Y, Gould D, Podhajcer O: Gene therapy for
autoimmune diseases: quo vadis? Nat Rev Immunol 2004, 4:
800-811.
2. Chernajovsky Y, Vessillier S, Adams G, Gofur Y, Subang MC,
Annenkov A, Favorov P, Daly GM, Gould DJ: Development of
new molecules, vectors and cells for therapy of arthritis. Joint
Bone Spine 2003, 70:474-476.
3. Evans CH: Gene therapy: what have we accomplished and
where do we go from here? J Rheumatol 2005, 32:17-20.
4. Robbins PD, Evans CH, Chernajovsky Y: Gene therapy for
arthritis. Gene Ther 2003, 10:902-911.
5. van de Loo F, Smeets R, van den Berg W: Gene therapy in
animal models of rheumatoid arthritis: are we ready for the
patients? Arthritis Res Ther 2004, 6:183-196.
6. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR,
St Clair EW, Weisman M, Smolen J, Lipsky PE, et al.: Infliximab
in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:
149-155.
7. Emery P, Seto Y: Role of biologics in early arthritis. Clin Exp
Rheumatol 2003, 21:S191-S194.
8. Mpofu S, Fatima F, Moots RJ: Anti-TNF-alpha therapies: they
are all the same (aren’t they?). Rheumatology (Oxford) 2005,
44:271-273.
9. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM,
Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, et al.:
Gene transfer to human joints: progress toward a gene
therapy of arthritis. Proc Natl Acad Sci USA 2005, 102:8698-
8703.
10. Vessillier S, Adams G, Chernajovsky Y: Latent cytokines: devel-
opment of novel cleavage sites and kinetic analysis of their
differential sensitivity to MMP-1 and MMP-3. Protein Eng Des
Sel 2004, 17:829-835.
11. Adams G, Vessillier S, Dreja H, Chernajovsky Y: Targeting
cytokines to inflammation sites. Nat Biotechnol 2003,  21:
1314-1320.
12. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld RA: Immuno-
cytokines: a promising approach to cancer immunotherapy.
Pharmacol Ther 1998, 80:277-292.
13. Nissim A, Gofur Y, Vessillier S, Adams G, Chernajovsky Y:
Methods for targeting biologicals to disease sites. Trends Mol
Med 2004, 10:269-274.
14. Jorgensen C, Noel D, Apparailly F, Sany J: Stem cells for repair
of cartilage and bone: the next challenge in osteoarthritis and
rheumatoid arthritis. Ann Rheum Dis 2001, 60:305-309.
15. van der Kraan P, van de Loo F, van den Berg W: Role of gene
therapy in tissue engineering procedures in rheumatology:
the use of animal models. Biomaterials 2004, 25:1497-1504.
16. Lewis DL, Wolff JA: Delivery of siRNA and siRNA expression
constructs to adult mammals by hydrodynamic intravascular
injection. Methods Enzymol 2005, 392:336-350.
17. Wells DJ: Opening the floodgates: clinically applicable hydro-
dynamic delivery of plasmid DNA to skeletal muscle. Mol Ther
2004, 10:207-208.
18. Gould DJ, Favorov P: Vectors for the treatment of autoimmune
disease. Gene Ther 2003, 10:912-927.
19. Chernajovsky Y, Adams G, Podhajcer OL, Mueller GM, Robbins
PD, Feldmann M: Inhibition of transfer of collagen-induced
arthritis into SCID mice by ex vivo infection of spleen cells
with retroviruses expressing soluble tumor necrosis factor
receptor. Gene Ther 1995, 2:731-735.
20. Annenkov A, Chernajovsky Y: Engineering mouse T lympho-
cytes specific to type II collagen by transduction with a
chimeric receptor consisting of a single chain Fv and TCR
zeta. Gene Ther 2000, 7:714-722.
21. Nakajima A, Seroogy CM, Sandora MR, Tarner IH, Costa GL,
Taylor-Edwards C, Bachmann MH, Contag CH, Fathman CG:
Antigen-specific T cell-mediated gene therapy in collagen-
induced arthritis. J Clin Invest 2001, 107:1293-1301.
22. Apparailly F, Millet V, Noel D, Jacquet C, Sany J, Jorgensen C:
Tetracycline-inducible interleukin-10 gene transfer mediated
by an adeno-associated virus: application to experimental
arthritis. Hum Gene Ther 2002, 13:1179-1188.
Available online http://arthritis-research.com/content/7/6/227